Healthcare
Denali Therapeutics Inc.(DNLI)
Live Price
Offline$24.07
+3.24% today
1Y Change
+61.31%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $3.00B
- Revenue Growth
- 0.0%
- EPS Growth
- -15.6%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Denali Therapeutics Inc. (DNLI) is a Healthcare stock with a market cap of $3.00B and listed on NASDAQ. The stock last traded around $24.07 and up 61.3% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -15.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -15.6%, free cash flow -16.1% with operating margin 0.0% and ROIC -52.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DNLI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -15.6%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +7.9% | +2.9% | +3.9% |
2026 Feb 26, 2026 | +2.7% | -1.1% | -8.0% | -7.9% |
2025 Nov 6, 2025 | +2.6% | +4.2% | +19.0% | +38.5% |
Benchmark Edge
DNLI vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DNLI
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DNLI Max Drawdown
-20.49%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DNLI and SPY.
Company Overview
Denali Therapeutics Inc.
NASDAQ Global Select
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
- Leadership
- Ryan J. Watts
- IPO Date
- Dec 8, 2017
- Employees
- 443
- Street Address
- 161 Oyster Point Boulevard
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 866 8548
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 3.3
Growth
- Revenue
- 0.0%
- EPS
- -15.6%
- Free Cash Flow
- -16.1%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -50.1%
- ROIC
- -52.6%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 9.16
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.